Immunotherapy in Hodgkin Lymphoma

Hodgkin lymphoma (HL) is a B-cell lymphoid malignancy. Although treatment outcomes for HL are generally favorable, relapsed/refractory cases can be challenging to manage. Immunotherapy has emerged as an important treatment option, especially for patients who do not respond to traditional therapies. In this chapter, we focus on immune checkpoint inhibitors. Nivolumab and Pembrolizumab are monoclonal [...]